AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$254.64-0.05%
Close 2026-07-07 · 1-day change
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→QuarterlyIQ Insights · ABBV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2026 have not been finalized and are subject to our financial statement closing procedures. The…
Regulation FD Disclosure On June 22, 2026, AbbVie Inc. (the “Company”) and Apogee Therapeutics, Inc. (“Apogee”) issued a joint press release announcing a definitive agreement pursuant to which the Company will acquire Apogee, on the terms and subject to the conditions set forth therein. The press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. On June 22, 2026, representatives of the Company will present information about the proposed transaction to various in…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: April 29, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2026 are expected to include acquired IPR&D and milestones expense of $744 million on a pre-tax basis, representing an unfavorable impact of $0.41 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2026 have not been finalized and are subject to our financial statement closing procedures. The…
Other Events. On March 4, 2026, AbbVie Inc. (“ AbbVie ”) completed its previously announced underwritten public offering (the “ Notes Offering ”) of $750,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “ Floating Rate Notes ”), $1,500,000,000 aggregate principal amount of its 3.775% senior notes due 2028 (the “ 2028 Notes ”), $1,250,000,000 aggregate principal amount of its 4.125% senior notes due 2031 (the “ 2031 Notes ”), $1,250,000,000 aggregate principal…
Other Events. On February 24, 2026, AbbVie Inc. (“ AbbVie ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein (collectively, the “ Underwriters ”), pursuant to which AbbVie agreed to issue and sell to the Underwriters $750,000,000 aggregate principal amount…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: February 4, 2026 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2025 are expected to include acquired IPR&D and milestones expense of $1.3 billion on a pre-tax basis, representing an unfavorable impact of $0.71 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2025 have not been finalized and are subject to our financial statement closing procedures.…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: October 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis, representing an unfavorable impact of $1.50 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2025 have not been finalized and are subject to our financial statement closing procedures.…
Regulation FD Disclosure On September 11, 2025, AbbVie announced that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, which AbbVie markets as RINVOQ. Given the settlement and license agreements, which are subject to standard acceleration provisions, assuming pediatric exclusivity is granted, no generic entry for any upadacitinib tablets is expected pri…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: July 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. The…
Class III director — Thomas J. Falk: AbbVie expanded its Board and appointed Thomas J. Falk as a new director.
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: April 25, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis, representing an unfavorable impact of $0.13 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. The…
Other Events. On February 26, 2025, AbbVie Inc. (“ AbbVie ”) completed its previously announced underwritten public offering (the “ Notes Offering ”) of $1,250,000,000 billion in aggregate principal amount of its 4.650% senior notes due 2028 (the “ 2028 Notes ”), $1,000,000,000 in aggregate principal amount of its 4.875% senior notes due 2030 (the “ 2030 Notes ”), $1,000,000,000 in aggregate principal amount of its 5.200% senior notes due 2035 (the “ 2035 Notes ”) and $750,000,000 in aggregat…
Other Events. On February 18, 2025, AbbVie Inc. (“ AbbVie ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Barclays Capital Inc. and Mizuho Securities USA LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein (collectively, the “ Underwriters ”), pursuant to which AbbVie agreed to issue and sell to the Underwriters $1,250,000,000 in a…
Chairman — Richard A. Gonzalez: Richard A. Gonzalez is retiring as Chairman, succeeded by Robert A. Michael.
Other Events. Revolving Credit Agreement On January 30, 2025 (the “Effective Date”), AbbVie Inc. (“AbbVie”) entered into a revolving credit agreement (the “Revolving Credit Agreement”) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Revolving Credit Agreement establishes an unsecured revolving credit facility of up to $3.0 billion which matures on January 30, 2030. This facility enables AbbVie to borrow funds o…
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: January 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Material Impairments On January 9, 2025, AbbVie determined that it will record an impairment charge related to the emraclidine intangible asset acquired as part of the acquisition of Cerevel Therapeutics Holdings, Inc. On November 11, 2024, AbbVie announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint o…
Results of Operations and Financial Condition Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&D and milestones expense of $1.6 billion on a pre-tax basis, representing an unfavorable impact of $0.88 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2024 have not been finalized and are subject to our financial statement closing procedures.…
Controller — Kevin K. Buckbee: Kevin K. Buckbee plans to retire from the Controller role, and David R. Purdue has been appointed as the new Senior Vice President, Controller.
. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: October 30, 2024 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.